 |
submitted by /u/mvea [link] [comments] |
Profits drive the rising prices of MS drugs in the US, finds a new study based on interviews with four pharmaceutical executives published in Neurology. In Europe, the price of a drug is typically highest when it launches and declines over time. The opposite appears to be the case in the US.
Profits drive the rising prices of MS drugs in the US, finds a new study based on interviews with four pharmaceutical executives published in Neurology. In Europe, the price of a drug is typically highest when it launches and declines over time. The opposite appears to be the case in the US.
https://ift.tt/2KWOnZ5 November 28, 2019 at 05:19PM https://ift.tt/1R552o9
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment